“…Ten articles highlighted the importance of observing relevant national and regional regulations, especially regarding informed consent, which was often presented as a makeshift or actual solution ( 24 , 25 , 26 , 31 , 32 , 34 , 35 , 36 , 41 , 43 ). However, it was noted that existing regulation may not be adequate to address issues of interoperability, efficiency, and duties owed to patients and to scientific progress; and there were calls for discussion within the field of clinical proteomics ( 32 , 33 , 35 , 36 , 38 , 39 , 41 ).…”